Genotype Information and Functional Testing Study
- Conditions
- Coronary Artery Disease
- Registration Number
- NCT00992420
- Lead Sponsor
- Scripps Health
- Brief Summary
This study is a sub-study of GRAVITAS (clinicaltrials.gov identifier NCT00645918). The purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to determine whether certain genes influence the incremental change in platelet reactivity with high-dose clopidogrel maintenance dosing in patients who have high residual platelet reactivity on standard dosing.
- Detailed Description
AS DESCRIBED BY THE PI: This study is a sub-study of GRAVITAS (clinicaltrials.gov identifier NCT00645918). The purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to determine whether certain genes influence the incremental change in platelet reactivity with high-dose clopidogrel maintenance dosing in patients who have high residual platelet reactivity on standard dosing.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2000
- Patients meeting inclusion criteria for GRAVITAS who undergo VerifyNow blood sampling for VerifyNow P2Y12 platelet function testing and IVRS entry for GRAVITAS randomization/selection determination
- See GRAVITAS trial (ClinicalTrials.gov identifier: NCT00645918)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method residual platelet reactivity 6 months Outcome 1 is residual platelet reactivity the measurement
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Scripps Genomic Medicine
🇺🇸La Jolla, California, United States